MAJOR BLEEDING IN PATIENTS WITH EMBOLIC STROKE OF UNDETERMINED SOURCE TREATED WITH DABIGATRAN VERSUS ACETYLSALICYLIC ACID (RE-SPECT ESUS TRIAL)

RE-SPECT ESUS™ offers an opportunity to evaluate factors associated with bleeding risk in patients with embolic stroke of unknown source (ESUS) treated with dabigatran vs acetylsalicylic acid (ASA). RE-SPECT ESUS was a randomized, controlled trial (570 centers in 42 countries). Patients with ESUS